| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | AKT inhibitor VIII | GDSC1000 | pan-cancer | AAC | 0.039 | 0.2 |
| mRNA | salermide | CTRPv2 | pan-cancer | AAC | -0.051 | 0.2 |
| mRNA | BRD-K48477130 | CTRPv2 | pan-cancer | AAC | 0.063 | 0.3 |
| mRNA | JNJ-26854165 | GDSC1000 | pan-cancer | AAC | 0.039 | 0.3 |
| mRNA | BRD-K79669418 | CTRPv2 | pan-cancer | AAC | -0.058 | 0.3 |
| mRNA | CAL-101 | CTRPv2 | pan-cancer | AAC | -0.04 | 0.3 |
| mRNA | AM-580 | CTRPv2 | pan-cancer | AAC | -0.041 | 0.3 |
| mRNA | UNC0638:navitoclax (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.04 | 0.3 |
| mRNA | GSK461364 | CTRPv2 | pan-cancer | AAC | 0.035 | 0.3 |
| mRNA | Parthenolide | CTRPv2 | pan-cancer | AAC | -0.042 | 0.3 |